Entrada Therapeutics (TRDA) Net Margin (2023 - 2025)
Historic Net Margin for Entrada Therapeutics (TRDA) over the last 3 years, with Q3 2025 value amounting to 2737.3%.
- Entrada Therapeutics' Net Margin fell 26658000.0% to 2737.3% in Q3 2025 from the same period last year, while for Sep 2025 it was 168.32%, marking a year-over-year decrease of 1938700.0%. This contributed to the annual value of 31.12% for FY2024, which is 362700.0% up from last year.
- Per Entrada Therapeutics' latest filing, its Net Margin stood at 2737.3% for Q3 2025, which was down 26658000.0% from 2211.54% recorded in Q2 2025.
- Entrada Therapeutics' Net Margin's 5-year high stood at 81.09% during Q3 2023, with a 5-year trough of 2737.3% in Q3 2025.
- For the 3-year period, Entrada Therapeutics' Net Margin averaged around 464.99%, with its median value being 26.62% (2023).
- Per our database at Business Quant, Entrada Therapeutics' Net Margin skyrocketed by 2007700bps in 2024 and then tumbled by -26658000bps in 2025.
- Quarter analysis of 3 years shows Entrada Therapeutics' Net Margin stood at 22.7% in 2023, then soared by 113bps to 2.95% in 2024, then crashed by -92742bps to 2737.3% in 2025.
- Its Net Margin stands at 2737.3% for Q3 2025, versus 2211.54% for Q2 2025 and 84.39% for Q1 2025.